Evidence map›Paper›PMID 37300736›Full record

ArticleLa Radiologia medica2023

Explainable machine learning via intra-tumoral radiomics feature mapping for patient stratification in adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma.

Xinzhi Teng, Jiang Zhang, Xinyang Han, Jiachen Sun, Sai-Kit Lam, Qi-Yong Hemis Ai, Zongrui Ma, Francis Kar-Ho Lee, Kwok-Hung Au, Celia Wai-Yi Yip and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in La Radiologia medica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Xinzhi TengDepartment of Health Technology and Informatics, The Hong Kong Polytechnic University, Y921, Lee Shau Kee Building, Hung Hom, Kowloon, Hong Kong SAR, China.
Jiang ZhangDepartment of Health Technology and Informatics, The Hong Kong Polytechnic University, Y921, Lee Shau Kee Building, Hung Hom, Kowloon, Hong Kong SAR, China.
Xinyang HanDepartment of Health Technology and Informatics, The Hong Kong Polytechnic University, Y921, Lee Shau Kee Building, Hung Hom, Kowloon, Hong Kong SAR, China.
Jiachen SunDepartment of Health Technology and Informatics, The Hong Kong Polytechnic University, Y921, Lee Shau Kee Building, Hung Hom, Kowloon, Hong Kong SAR, China.
Sai-Kit LamDepartment of Biomedical Engineering, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong SAR, China.
Qi-Yong Hemis AiDepartment of Health Technology and Informatics, The Hong Kong Polytechnic University, Y921, Lee Shau Kee Building, Hung Hom, Kowloon, Hong Kong SAR, China.
Zongrui MaDepartment of Health Technology and Informatics, The Hong Kong Polytechnic University, Y921, Lee Shau Kee Building, Hung Hom, Kowloon, Hong Kong SAR, China.
Francis Kar-Ho LeeDepartment of Clinical Oncology, Queen Elizabeth Hospital, Yau Ma Tei, Hong Kong SAR, China.
Kwok-Hung AuDepartment of Clinical Oncology, Queen Elizabeth Hospital, Yau Ma Tei, Hong Kong SAR, China.
Celia Wai-Yi YipDepartment of Clinical Oncology, Queen Elizabeth Hospital, Yau Ma Tei, Hong Kong SAR, China.
James Chung Hang ChowDepartment of Clinical Oncology, Queen Elizabeth Hospital, Yau Ma Tei, Hong Kong SAR, China.
Victor Ho-Fun LeeDepartment of Clinical Oncology, The University of Hong Kong, Pok Fu Lam, Hong Kong SAR, China.
Jing CaiDepartment of Health Technology and Informatics, The Hong Kong Polytechnic University, Y921, Lee Shau Kee Building, Hung Hom, Kowloon, Hong Kong SAR, China. jing.cai@polyu.edu.hk.

Funding

Health and Medical Research Fund HMRF09200576Mainland-Hong Kong Joint Funding Scheme (MHKJFS) MHP/005/20Project of RISA P0043001Project of Strategic Importance Fund P0035421Shenzhen Basic Research Program JCYJ20210324130209023Shenzhen-Hong Kong-Macau S&T Program (Category C) SGDX20201103095002019
6 · The paper itself

Abstract

purposeThis study aimed to discover intra-tumor heterogeneity signature and validate its predictive value for adjuvant chemotherapy (ACT) following concurrent chemoradiotherapy (CCRT) in locoregionally advanced nasopharyngeal carcinoma (LA-NPC). MATERIALS AND

methods397 LA-NPC patients were retrospectively enrolled. Pre-treatment contrast-enhanced T1-weighted (CET1-w) MR images, clinical variables, and follow-up were retrospectively collected. We identified single predictive radiomic feature from primary gross tumor volume (GTVnp) and defined predicted subvolume by calculating voxel-wised feature mapping and within GTVnp. We independently validate predictive value of identified feature and associated predicted subvolume.

resultsOnly one radiomic feature, gldm_DependenceVariance in 3 mm-sigma LoG-filtered image, was discovered as a signature. In the high-risk group determined by the signature, patients received CCRT + ACT achieved 3-year disease free survival (DFS) rate of 90% versus 57% (HR, 0.20; 95%CI, 0.05-0.94; P = 0.007) for CCRT alone. The multivariate analysis showed patients receiving CCRT + ACT had a HR of 0.21 (95%CI: 0.06-0.68, P = 0.009) for DFS compared to those receiving CCRT alone. The predictive value can also be generalized to the subvolume with multivariate HR of 0.27 (P = 0.017) for DFS.

conclusionThe signature with its heterogeneity mapping could be a reliable and explainable ACT decision-making tool in clinical practice.

Indexed as

Nasopharyngeal NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsChemoradiotherapyChemotherapy, AdjuvantCisplatinHumansLevamisoleNasopharyngeal CarcinomaRetrospective Studies3-aminolevamisoleCisplatinLevamisoleAdjuvant chemotherapyNPCRadiomicsTumor heterogeneity map

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.